Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия
Список исп. литературыСкрыть список 1. ESC/EAS Guidelines for the management of dyslipidaemias 2019: lipid modification to reduce cardiovascular risk. Eur Heart J 2019; 00: 1–78. DOI: 10.1093/eurheartj/ehz455 2. Rosengren A. Better treatment and improved prognosis in elderly patients with AMI: but do registers tell the whole truth? Eur Heart J 2012; 33 (5): 562–3. DOI: 10.1093/eurheartj/ehr364 3. Prospective Studies C, Lewington S, Whitlock G et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007; 370 (9602): 1829–39. DOI: 10.1016/ S0140–6736(07)61778–4 4. Thompson PD, Panza G, Zaleski A, Taylor B. Statin-Associated Side Effects. J Am Coll Cardiol 2016; 67 (20): 2395–410. DOI: 10.1016/j.jacc.2016.02.071 5. Statin side effects: Weigh the benefits and risks. Mayo Clinic Staff 2016. URL: mayoclinic.org/diseases-conditions/high-blood-cholesterol/in-depth/statin-side-effects/art-20046013?pg=1 6. Драпкина О.М., Чернова Е.М. Миопатия как побочный эффект терапии статинами: механизмы развития и перспективы лечения. Рациональная фармакотерапия в кардиологии. 2015; 1. [Drapkina O.M., Chernova E.M. Myopathy as a side effect of statin therapy: mechanisms of development and treatment prospects. Ratsional'naia farmakoterapiia v kardiologii. 2015; 1 (in Russian).] 7. Rosenson RS et al. Statin muscle-related adverse events. Accessed Jan. 25, 2019. URL: https://www.uptodate.com/contents/search. 8. Напалков Д.А. Безопасность статинов: что нужно знать практикующему врачу. Рациональная фармакотерапия в кардиологии. 2014; 10 (3); 334–8. [Napalkov D.A. Bezopasnost' statinov: chto nuzhno znat' praktikuiushchemu vrachu. Ratsional'naia farmakoterapiia v kardiologii. 2014; 10 (3); 334–8 (in Russian).] 9. Hansen KE., Hildebrand JP, Ferguson EE et al. Arch Intern Med 2005; 165: 2671–6. 10. Bruckert E, Hayem G, Dejager S et al. Cardiovasc Drugs Ther. 2005; 19: 403–14; Cholesterol Treatment Trialists (CTT) Cjllaboration. Efficacy and safety of more intensive lovering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010; 376; 1670–80. 11. Bruckert E, Hayem G, Dejager S et al. Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients – The PRIMO Study. Cardiovasc Drugs Ther 2005; 19 (6): 403–14. DOI: 10.1007/s10557-005-5686-z 12. Langeard A, Saillant K, Cloutier EC et al. Association between Statin Use and Balance in Older Adults. Int J Environ Res Public Health 2020; 17 (13): 4662. DOI: 10.3390/ijerph17134662 13. Rothschild DP, Novak E, Rich MW. Effect of Statin Therapy on Mortality in Older Adults Hospitalized with Coronary Artery Disease: A Propensity-Adjusted Analysis. J Am Geriatr Soc 2016; 64 (7): 1475–9.